Molecular structure of Miltefosine, CAS Number: 58066-85-6
Miltefosine (CAS 58066-85-6)
See product citations (8)
Alternate Names:
1-Hexadecylphosphorylcholine
Application:
Miltefosine is a PI 3-kinase and Akt inhibitor that also inhibits anti-IgE induced histamine release
CAS Number:
58066-85-6
Purity:
>98%
Molecular Weight:
407.6
Molecular Formula:
C21H46NO4P
Supplemental Information:
This is classified as a Dangerous Good for transport and may be subject to additional shipping charges.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Mitefosine, a PI 3-kinase and Akt inhibitor belonging to the alkylphosphocholines, has also been shown to inhibit anti-IgE induced histamine release from skin mast cells. Experimental studies show that this agent can reduce cytokines IL-1beta, IL-4, and IL-6 in certain skin tissue cells and also strongly impede the esterification of cholesterol. Additionally, Miltefosine displays the ability to methylate CDP-choline (sc-200713) and phosphatidylethanolamine which interferes with biosynthesis of phosphatidylcholine. Furthermore, data suggests that this compound can slow down the formation of sphingomyelin, which promotes intracellular accumulation of ceramide. Miltefosine is an inhibitor of CCT and PKC.
Miltefosine (CAS 58066-85-6) References
- Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. | Chugh, P., et al. 2008. Retrovirology. 5: 11. PMID: 18237430
- The putative lipid raft modulator miltefosine displays immunomodulatory action in T-cell dependent dermal inflammation models. | Bäumer, W., et al. 2010. Eur J Pharmacol. 628: 226-32. PMID: 19917276
- Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids. | Jiménez-López, JM., et al. 2010. Lipids Health Dis. 9: 33. PMID: 20338039
- Could miltefosine be used as a therapy for toxoplasmosis? | Eissa, MM., et al. 2015. Exp Parasitol. 157: 12-22. PMID: 26112396
- Miltefosine Reduces the Cytolytic Activity and Virulence of Acinetobacter baumannii. | Fiester, SE., et al. 2019. Antimicrob Agents Chemother. 63: PMID: 30373804
- Miltefosine enhances the fitness of a non-virulent drug-resistant Leishmania infantum strain. | Eberhardt, E., et al. 2019. J Antimicrob Chemother. 74: 395-406. PMID: 30412253
- Miltefosine increases macrophage cholesterol release and inhibits NLRP3-inflammasome assembly and IL-1β release. | Iacano, AJ., et al. 2019. Sci Rep. 9: 11128. PMID: 31366948
- Efficacy of miltefosine therapy against subcutaneous experimental pythiosis in rabbits. | Loreto, ES., et al. 2020. J Mycol Med. 30: 100919. PMID: 31901425
- Oral Miltefosine as Salvage Therapy for Refractory Acanthamoeba Keratitis. | Thulasi, P., et al. 2021. Am J Ophthalmol. 223: 75-82. PMID: 33045218
- Efficacy and Tolerability of Miltefosine in the Treatment of Cutaneous Leishmaniasis. | Ware, JM., et al. 2021. Clin Infect Dis. 73: e2457-e2562. PMID: 33124666
- Efficacy of topical Miltefosine formulations in an experimental model of cutaneous leishmaniasis. | Peralta, MF., et al. 2022. Drug Deliv Transl Res. 12: 180-196. PMID: 33502733
- Miltefosine Against Scedosporium and Lomentospora Species: Antifungal Activity and Its Effects on Fungal Cells. | Rollin-Pinheiro, R., et al. 2021. Front Cell Infect Microbiol. 11: 698662. PMID: 34368017
- Lipid raft-disrupting miltefosine preferentially induces the death of colorectal cancer stem-like cells. | Park, SY., et al. 2021. Clin Transl Med. 11: e552. PMID: 34841679
- Evolutionary aspect of Miltefosine transporter proteins in Leishmania major. | Kabra, R. and Singh, S. 2022. Adv Protein Chem Struct Biol. 130: 399-418. PMID: 35534115
- Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis. | Mohammad, N., et al. 2022. J Ayub Med Coll Abbottabad. 34: 849-853. PMID: 36566412
Inhibitor of:
Akt, ATP8A2, C12orf11, CCT, CDS1, CLPTM1L, DGK-δ, Ethanolamine kinase 2, FAM185A, FAPP1, GAP-assoc p62, GDPD4, ILKAP, INPP5B, LPAAT-γ, LPCAT1, LYPLA1, MAGI-3, MTMR15, MULK, Nir2, PAF Acetylhydrolase, PAFAH1B3, PAP-2a, PCYT2, PHF14, PI 3-kinase, PI 4-kinase II β, PIG-N, PIG11, PKB Kinase, PKC, PLC δ3, PLC η1, PLC ζ, PLC 2, PLC-L, PLCδ1, PLEKHA6, PLP-Cα, PLP-Cβ, PLP-Cδ, PLRP1, PPAPDC2, PPAPDC3, PSS2 (PTDSS2; phosphatidylserine synthase 2), SAC1_Sac1, Sec23IP, Ser/Thr Protein Kinase, StARD7, TMEM55A, Type I 5-phosphatase, UEV3, and WBSCR9.Activator of:
ATP10A, ATP8B, DGS8, FIC1, FTS, LPPR2, LPPR4, MORN4, MS4A15, MTMR5, PC-PLD4, PIG-C, PLC-L, PLSCR3, PSS1, and TMEM34.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Miltefosine, 50 mg | sc-203135 | 50 mg | $81.00 |